Highlights of This Issue 567

REVIEW

569 Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment
Enrique Grande, Maria-Victoria Bolós, and Edurne Arriola

577 GPR54 Is a Target for Suppression of Metastasis in Endometrial Cancer
Hyun Sook Kang, Tsukasa Baba, Masaki Mandai, Noriomi Matsumura, Junzo Hamanishi, Budiman Kharma, Eiji Kondoh, Yumiko Yoshioka, Shinya Oishi, Nobutaka Fujii, Susan K. Murphy, and Ikuo Konishi

591 Targeting the ReplicationCheckpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Timothy J. Guzi, Kamil Paruch, Michael P. Dwyer, Marc Labroli, Frances Shanahan, Nicole Davis, Lorena Taricani, Derek Wiswell, Wolfgang Seghezzi, Ervin Penafior, Bhagyashree Bhagwat, Wei Wang, Danling Gu, Yunsheng Hsieh, Suining Lee, Ming Liu, and David Parry

603 Targeted Delivery of an Antibody–Mutant Human Endostatin Fusion Protein Results in Enhanced Antitumor Efficacy
Seung-Uon Shin, Hyun-Mi Cho, Jaime Merchan, Jin Zhang, Krisztina Kovacs,Yawu Jing, Sundaram Ramakrishnan, and Joseph D. Rosenblatt

Preclinical Development

Context Dependence of Checkpoint Kinase 1 as a Therapeutic Target for Pancreatic Cancers Deficient in the BRCA2 Tumor Suppressor
Hiroyoshi Hattori, Ferdinandos Skoulidis, Paul Russell, and Ashok R. Venkitaraman

679 Rapamycin Reverses Splenomegaly and Inhibits Tumor Development in a Transgenic Model of Epstein-Barr Virus–Related Burkitt’s Lymphoma
Osman Cen and Richard Longnecker
MOLECULAR MEDICINE IN PRACTICE

Gene Expression Profiling Provides Insights into Pathways of Oxaliplatin-Related Sinusoidal Obstruction Syndrome in Humans
Laura Rubbia-Brandt, Sébastien Tauzin, Catherine Brezault, Céline Delucinge-Vivier, Patrick Descombes, Bertrand Dousset, Pietro E. Majno, Gilles Mentha, and Benoit Terris

Evasion Mechanisms to Igf1r Inhibition in Rhabdomyosarcoma

ABOUT THE COVER

Genetically-engineered mouse models often represent some of the most physiologically accurate models of cancer from which to understand the tumor microenvironment and with which to perform preclinical trials. Abraham and colleagues present studies of a prototypic insulin-like growth factor receptor inhibitor using both genetically-engineered mouse models and the shell-free quail chorioallantois membrane (CAM) assay. Remarkably, the inexpensive short term (2 week) CAM assay offers xenografted tumors a scaffold of lymphatics, arteries, and veins that mimic short-term in vivo growth with all the advantages of intravital imaging. Photograph credits, Elaine Huang and Audra Lee. For details, see article by Abraham and colleagues on page 697.